Nxera Pharma (SOLTF) Stock Price, News & Analysis
Company Description
Nxera Pharma (OTC Link: SOLTF) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $618.5M.
SOLTF has declined 1.0% over the past year. Shares last traded at $5.63.
This page collects what Stock Titan holds for SOLTF, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Nxera Pharma (SOLTF) stock last closed at $5.63. Over the past 12 months, the stock has lost 1.0%. At a market capitalization of $618.5M, SOLTF is classified as a small-cap stock with approximately 92.6M shares outstanding.
Latest News
Nxera Pharma has 8 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 1 with negative movement. Key topics include earnings, AI, clinical trial, management. View all SOLTF news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Nxera Pharma (SOLTF) currently stands at 1.8 million shares, down 1.3% from the previous reporting period, representing 2.3% of the float. This relatively low short interest suggests limited bearish sentiment. With 1000.0 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for Nxera Pharma (SOLTF) currently stands at 1000.0 days. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The ratio has shown significant volatility over the period, ranging from 126.8 to 1000.0 days.
SOLTF Company Profile & Sector Positioning
Nxera Pharma (SOLTF) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing SOLTF often look at related companies in the same sector, including Pharming Group (PHGUF), Oxford Biomedica (OXBDF), Sanbio (SNBOY), Northwest Bio (NWBO), and Cytodyn Inc (CYDY). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SOLTF's relative position within its industry.